• AAPL 169.02
  • TSLA 162.13
  • AMZN 176.59
  • MSFT 409.06
  • INTC 34.5
  • EURUSD 1.0727
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. KO /
  3. 000070.KO

Samyang Holdings (000070 KO) stock market data APIs

₩68500 400(0.6%) as of April 25, 2024

Samyang Holdings Financial Data Overview

68100
68500
-
68900
68000
63000-81800
526 766 M
7 436 K
3 210 853 M
-659.54
0.0514
0.931
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '000070',
Type: 'Common Stock',
Name: 'Samyang Holdings',
Exchange: 'KO',
CurrencyCode: 'KRW',
CurrencyName: 'Korean Won',
CurrencySymbol: '₩',
CountryName: 'Korea',
CountryISO: 'KR',
ISIN: 'KR7000070003',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Industrials',
Industry: 'Conglomerates',
}

Samyang Holdings Fundamental Data is available in our Financial Data APIs

  • Net Revenue 3 210 853 M
  • EBITDA 208 147 M
  • Earnings Per Share
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Samyang Holdings Earnings via APIs

  • Latest Release 2024-02-06
  • EPS/Forecast NaN

Get Samyang Holdings End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Samyang Holdings latest news via APIs

Samyang Holdings Presents Clinical Cases of 'Lafullen® and Croquis®' at KOAT Academic Conference

Presentation of "Lafullen®" and "Croquis®" Procedures and Clinical Cases... Confirming Product Excellence and Safety Biodegradable Polymer Filler "Lafullen®" Maintains Natural Volume for 2 Years "C...

Samyang Signs Partnership Agreement with Yxintent, China for Dermal Filler Lafullen®

Yxintent will exclusively sell Lafullen® after conducting clinical trials and approval in China, with Samyang supplying products worth KRW 100 billion over the next five years Long-lasting biodegrada...
Do you have any questions?
support@eodhistoricaldata.com